EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis

Thomaz Alexandre Costa, Luma Maria Tavares de Sousa, Alleh Nogueira, Gabriel Cavalcante Lima Chagas, Marconi Abreu, Larry A Allen, William K Cornwell, Josephine Harrington

Heart Failure Reviews · 06.06.2026 · 31 (1)

DOI: 10.1007/s10741-026-10641-3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Heart Failure Reviews, online erschienen am 06.06.2026. Verfasst von Thomaz Alexandre Costa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Heart Transplantation, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are recommended for multiple populations-type 2 diabetes (T2D), chronic kidney disease, and heart failure-but their role after heart transplant (HTX) remains unclear. We searched PubMed, Cochrane, and Embase for studies of HTX recipients with T2D comparing outcomes in SGLT2i users vs. non-users. Outcomes of interest were all-cause mortality, urinary tract infection (UTI), and estimated glomerular filtration rate (eGFR) change from baseline. Odds ratios (ORs) and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were pooled using a random-effects model for binary outcomes. Three retrospective observational studies were included in the all-cause mortality meta-analysis, four in the UTI incidence meta-analysis, and five in the qualitative analysis evaluating eGFR change (n = 3,564). Mean follow-up ranged from 9 to 83 months. SGLT2i use was associated with a lower risk of all-cause mortality compared with non-use in both unadjusted (OR 0.43; 95% CI 0.26-0.71; p < 0.001; I² = 79%) and adjusted analyses (aHR 0.69; 95% CI 0.51-0.93; p = 0.02; I² = 20%), without increasing the risk of UTI (OR 0.77; 95% CI 0.14-4.05; p = 0.75; I² = 48%). Most studies suggested stable or increased eGFR from baseline with SGLT2i exposure. SGLT2i use, compared with non-use, was associated with lower all-cause mortality without an increased incidence of UTIs in HTX recipients with T2D. Additionally, the pooled data suggest a possible renal benefit. The totality of these observational data, despite their limitations, provide important context for ongoing SGLT2i use following HTX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Heart TransplantationSodium-Glucose Transporter 2 InhibitorsHeart FailureHumansGlomerular Filtration RateTreatment Outcome

Stichwörter der Autor:innen

All-cause mortalityHeart transplantMeta-analysisSGLT2 inhibitorsType 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
  • Department of Medicine, University of Miami, Miami, FL, USA.
  • Postgraduate Program in Cardiovascular Sciences, Federal University of Ceara, Ceara, Brazil.
  • Postgraduate Program in Cardiology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
  • MOVE Academic Research Organization, Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.

Zitieren

APA

Costa, T. A., de Sousa, L. M. T., Nogueira, A., Chagas, G. C. L., Abreu, M., Allen, L. A., Cornwell, W. K., & Harrington, J. (2026). Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis. Heart Failure Reviews, 31(1). https://doi.org/10.1007/s10741-026-10641-3

Vancouver

Costa TA, de Sousa LMT, Nogueira A, Chagas GCL, Abreu M, Allen LA, et al. Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis. Heart Failure Reviews. 2026;31(1). doi:10.1007/s10741-026-10641-3

BibTeX
@article{Costa2026,
  author = {Costa, Thomaz Alexandre and de Sousa, Luma Maria Tavares and Nogueira, Alleh and Chagas, Gabriel Cavalcante Lima and Abreu, Marconi and Allen, Larry A and Cornwell, William K and Harrington, Josephine},
  title = {Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis},
  journal = {Heart Failure Reviews},
  year = {2026},
  volume = {31},
  number = {1},
  doi = {10.1007/s10741-026-10641-3}
}
Kostenlos starten →